Nanologica Takes Order from Insulin Manufacturer for Production

Nanologica AB (publ) has taken an order for the company’s silica for preparative chromatography for evaluation in production scale, from one of the world’s largest manufacturers of insulin. If the products meet the customer’s expectations, Nanologica expects commercial deliveries within a year.

Nanologica has been working with customers within preparative chromatography since 2016 and several customers have successfully evaluated the company’s silica for preparative chromatography, NLAB Saga®, in various stages. Nanologica has been collaborating with one of these customers for a long time regarding reducing the customer’s costs for the production of insulin and other diabetes products. In connection with Nanologica now having a finished product at its large-scale production facility, the customer can now evaluate NLAB Saga® in full-scale production for the first time.

Nanologica provides products free of charge in return for being shared with results and transparency in the final evaluation. The customer finances all other costs of tests in full-scale production. In the event of a positive outcome, Nanologica expects negotiations on deliveries longterm starting within a year.

This order is perhaps the most important milestone to date for Nanologica. We have shown that we can produce on a large scale and we have customers who are prepared to test our material in full-scale production. We have been working for a long time to be able to take this step and we are now truly embarking on our journey in preparative chromatography, an area that within a few years will be able to generate significant profitability for the company”, CEO Andreas Bhagwani comments.

Since 2019, Nanologica has invested in scaling up the production volume so that NLAB Saga® can be used for preparative chromotography, which is used in insulin manufacturing, among other things.  The company has developed the capacity to manufacture on a tonal scale at a production facility in the UK, where the production of the first major volumes have recently been finalized.

Thanks to the high quality of Nanologica’s silica NLAB Saga®, Nanologica’s commercial potential in preparative chromatography is estimated to be large. The company intends to conduct sales directly and together with partners in all major markets – India, China, the US, and Europe – and has a goal of achieving sales in preparative chromatography of MSEK 100–300 by 2024.


For further information, please contact:

Johanna Johansson, Director IR, Communications and Marketing
Ph: +46 72 211 21 90 or e-mail:


About Nanologica AB (publ)
Nanologica manufactures, develops, and sells nanoporous silica particles for applications within life science. Nanologica is world-leading in controlling the shape, size, porosity, and surface properties of silica particles, creating opportunities to develop unique products. Through the two business areas, Drug Development and Chromatography, the company strives towards increasing the accessibility of innovative treatments and medicines in healthcare, for the benefit of patients around the world. In Chromatography, the company aims to make insulin and other peptide drugs available to more patients in need, by lowering the cost of manufacturing. In Drug Development, Nanologica develops a unique drug delivery platform for local delivery of drugs to the lung, to provide new treatment options for patients with lung diseases. Nanologica is headquartered in Södertälje, and the company’s share (NICA) is listed for trade on Nasdaq Stockholm Main Market since 29 mars, 2022. For further information, please visit

The information is information that Nanologica AB is obliged to make public pursuant to the EU Market Abuse Regulatio). The information was submitted for publication, through the agency of the contact persons above, on August 11, 2022, at 10.55 (CET).


2022-08-11 Nanologica Takes Order from Insulin Manufacturer for Production

Share this: